drugset
drugset / Trial / NCT05908786

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

NCT05908786 ↗

Phase 1/2 Completed 62 enrolled Hoffmann-La Roche
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC. The study is designed with the flexibility to open new treatment arms as new agents become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population.

Timeline

Start
2023-12-05
Primary completion
2025-08-27
Completion
2025-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 1200 mg Intravenous
Subject Bevacizumab Monoclonal antibody 15 mg/kg Intravenous
Subject Tiragolumab Monoclonal antibody 600 mg Intravenous
Subject Tobemstomig Monoclonal antibody 600 mg Intravenous

Indications

hepatocellular carcinoma